07:42 AM EDT, 08/20/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Tuesday that the US Food and Drug Administration has approved Rybrevant in combination with Lazcluze for treating adult patients with locally advanced or metastatic non-small cell lung cancer who have epidermal growth factor receptor exon 19 deletions or exon 21 L858R mutations.

The combination therapy's safety profile was consistent with that of the individual treatments, with venous thromboembolic events reported, the company said. Adverse event rates were consistent with other Rybrevant treatments.

Price: 159.90, Change: +0.27, Percent Change: +0.17